SNN

Based on Smith & Nephew plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Smith & Nephew do?

Smith & Nephew develops and sells medical devices across three main areas: orthopedic reconstruction (knee and hip implants), sports medicine and ENT (minimally invasive surgical tools and arthroscopic systems), and advanced wound management (dressings, biologics, and bioactive wound care products). Its devices are used by surgeons and healthcare providers in hospitals worldwide.

Does SNN pay dividends?

Yes, Smith & Nephew pays a regular dividend. This is relatively uncommon among growth-focused medtech peers and reflects the company's established, diversified revenue base. Investors seeking income alongside capital exposure to the medical device sector may find this characteristic relevant to their screening criteria.

When does SNN report earnings?

Smith & Nephew reports financial results on a regular cadence as required by its listing obligations. For precise reporting dates and the most recent results, investors should consult Smith & Nephew's official investor relations page directly.

Is SNN a good stock to buy?

UQS Score rates SNN as Good overall. The Valuation pillar is Attractive and the Quality pillar is Good, while Moat and Growth are both Neutral. Whether SNN fits a portfolio depends on individual goals and risk tolerance. The complete pillar breakdown is available to Pro members on uqs-score.com.

Is SNN overvalued?

Based on the UQS framework, SNN's Valuation pillar is rated Attractive, suggesting the stock is not considered expensive relative to its fundamental profile. This does not constitute a price prediction, but it does indicate the market may be pricing in limited near-term upside expectations for the business.

How does SNN compare to its competitors?

Smith & Nephew competes broadly in the medical device space, though its listed peers — Insulet, Align Technology, and Penumbra — each focus on distinct clinical niches. SNN's diversification across orthopedics, sports medicine, and wound care distinguishes it from more narrowly focused device companies. Full UQS comparisons are available on each ticker's page.

What is SNN's market cap bracket?

Smith & Nephew is classified as a large-cap company. This places it among the more established names in the global medical device sector, with the scale to support a broad product portfolio, international distribution, and ongoing research and development investment.

Who founded Smith & Nephew?

Smith & Nephew traces its origins to a pharmacy business founded in the nineteenth century in Hull, England. The modern corporate structure reflects decades of mergers, acquisitions, and strategic evolution. Detailed founding history is widely available through the company's official corporate history resources.

Is SNN a long-term quality stock?

As a long-term quality indicator, SNN's UQS profile shows Good Quality and an Attractive Valuation, which are constructive signals for patient investors. However, Neutral ratings on Moat and Growth suggest the company may need to demonstrate stronger competitive differentiation or revenue acceleration to earn a higher long-term quality designation.

What is the main competitive advantage of Smith & Nephew?

Smith & Nephew's breadth across orthopedic reconstruction, sports medicine, and wound care provides diversification that single-segment device companies lack. Its established relationships with hospital systems and surgeons, combined with a portfolio of proprietary implants and enabling technologies, form the foundation of its competitive position — though the UQS Moat pillar currently rates this as Neutral.

What sector does SNN belong to?

Smith & Nephew operates in the Healthcare sector, specifically within the medical devices and equipment industry. It serves surgical and wound care markets globally, making it sensitive to trends in elective procedure volumes, hospital spending, and healthcare policy across its key geographies.

Smith & Nephew plc shows solid profitability with healthy returns on capital and reasonable margins.

Smith & Nephew plc shows steady but unspectacular growth, typical for mature companies.

Smith & Nephew plc maintains a reasonable risk profile with manageable debt levels.

Smith & Nephew plc appears attractively valued relative to its earnings, cash flows, and sector peers.

Smith & Nephew plc possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SNN.

The UQS (Unified Quality Score) for Smith & Nephew plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Smith & Nephew plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Smith & Nephew plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.